ABSTRACT
Objective:To investigate and analyze the clinical application and adverse reactions of scopolamine butylbromide injection to promote the rational use in clinics. Methods:Totally 3695 effective cases treated with scopolamine butylbromide injection were collected from January 2016 to July 2017, and the age, sex, cause of drug use, medication days, combined use, high risk factors, and names, types and clinical manifestations of adverse reactions induced by scopolamine butylbromide were classified and statistically analyzed. Results:The overall incidence of adverse reactions of scopolamine butylbromide was 0.22%. The drug use rate was 44.36% in high-risk patients. The incidence of adverse drug reactions in high-risk patients was 1.83%,and that in low-risk patients was 0.24%, and the difference was 7.63 times. Combined drug use was common, and 1.98% of the combined use had potential drug interactions. Conclusion:The requirements of drug instructions should be strictly followed,and high-risk patients and drug combination should be paid much attention in order to reduce the risk of adverse drug reactions and ensure the drug safety.
ABSTRACT
OBJECTIVE:To observe the efficacy and safety of scopolamine butylbromide in the adjuvant treatment of gastric ul-cer. METHODS:The data of 160 patients with gastric ulcer were retrospectively analyzed and randomly divided into tradition group and combination group. Tradition group was orally treated with acid suppression,hemostasis and other conventional treatment. Based on the treatment of tradition group,combination group was treated with Scopolamine butylbromide for injection 20 mg by in-tramuscular injection,once a day,for continuous 7 d,continue conventional treatment after 7 d. The treatment course was 8 weeks. The clinical efficacy,different complete relief patients with abdominal pain in different time,and the recurrence rate after 1 year in 2 groups were observed,and the incidence of adverse reactions were recorded. RESULTS:The total effective rate in combination group was significantly higher than tradition group,recurrence rate was significantly lower than tradition group,different complete relief patients with abdominal pain in different time were significantly better than tradition group,the difference was statistically sig-nificant(P<0.05). There were no obvious adverse reactions in 2 groups during treatment. CONCLUSIONS:Based on the conven-tional treatment,scopolamine butylbromide can be used in the adjuvant treatment of gastric ulcer. It can obviously shorten the time of abdominal pain in patients with gastric ulcer and reduce the recurrence rate,with good safety.
ABSTRACT
Clozapine has been demonstrated to be useful for treating refractory schizophrenia. However, hypersalivation occurs in 31.0-97.4% of the patients treated with clozapine. Accordingly, some patients who are disturbed by their hypersalivation refuse to continue with clozapine treatment. This study investigated the efficacy of the anticholinergic agent scopolamine butylbromide against clozapine-induced hypersalivation. Five schizophrenia patients were coadministered scopolamine butylbromide (30-60 mg/day) for 4 weeks. At the baseline and after 4 weeks' treatment, we subjectively evaluated hypersalivation using a visual analog scale and objectively assessed it using the Drooling Severity Scale and Drooling Frequency Scale. As a result, improvements in the patients' Drooling Severity Scale and Drooling Frequency Scale scores, but no improvements in their visual analog scale scores, were observed after scopolamine butylbromide treatment. These results indicate that at least some schizophrenic patients with clozapine-induced hypersalivation would benefit from scopolamine butylbromide treatment. We conclude that clozapine-induced hypersalivation is one factor of stress to patients. Subjective hypersalivation was not improved, but objective hypersalivation was, by scopolamine butylbromide treatment. However, scopolamine butylbromide and clozapine possess anticholinergic effects so clinicians should closely monitor patients who take scopolamine butylbromide.